DrugDeal Decode

Exploring the Latest RDC Deal by RayzeBio: A Guide to Rapidly Accessing Transaction Insights

25 January 2024
4 min read

On December 26, 2023, Bristol Myers Squibb (BMS) and RayzeBio jointly announced that they have reached a definitive merger agreement whereby Bristol Myers Squibb will acquire RayzeBio for $62.50 per share in cash, valuing the total equity at approximately $4.1 billion, which amounts to about $3.6 billion after deducting an estimated $500 million in cash on RayzeBio's balance sheet. The transaction is expected to be completed in the first half of 2024. RayzeBio holds a leading and innovative position in the field of targeted radiotherapy based on actinium. The company has disclosed three products, with RYZ101 being the most advanced and anticipated.

About RYZ-101

RYZ-101 is a radiopharmaceutical and diagnostic agent that falls under the category of Radionuclide Drug Conjugates (RDC). It primarily targets SSTR2, a receptor commonly found in various diseases. The drug has shown potential therapeutic applications in neoplasms, digestive system disorders, endocrinology and metabolic diseases, as well as respiratory diseases. Specifically, RYZ-101 has demonstrated efficacy in treating Gastro-Enteropancreatic Neuroendocrine Tumors (GEP-NETs), Non-Functioning Pancreatic Endocrine Tumors, and Extensive Stage Small Cell Lung Cancer. Click the image below to directly embark on the exploration journey with the RYZ-101!

Currently, RYZ101 is in Phase 3 clinical trials for patients with SSTR-positive GEP-NETs, and clinical trials for the treatment of extensive-stage small cell lung cancer (ES-SCLC) have entered Phase 1. If the Phase 3 clinical trials of RYZ101 are successful, it has the potential to become the world's first actinium-225 radiopharmaceutical.

About Rayzebio

Rayzebio, Inc. is a biomedicine organization founded in 2018 and based in California, United States. The company has a strong focus on developing therapeutics for Neoplasms, with the highest drug count in this therapeutic area. It is also actively involved in developing treatments for Digestive System Disorders and Urogenital Diseases. The most frequently developed targets by Rayzebio, Inc. include EphA2 and GPC3. The company has a pipeline of drugs at various stages of development, with a significant number of drugs in the Preclinical phase. It has also progressed to Phase 2 and Phase 3 for some of its candidates. However, it has not yet received regulatory approval for any of its drugs. This information provides an objective overview of Rayzebio, Inc.'s activities in the pharmaceutical industry.

How to get the latest progress on drug deals?

If you would like to access the latest transaction event information, you can click on the 'Deal' module from the homepage of the Synapse database. Within the Deal module, you can search for global pharmaceutical transaction information using labels such as Drugs, Organization, Target, Drug Type, Deal Date. 

图形用户界面, 文本, 应用程序, 电子邮件

描述已自动生成

Furthermore, you can obtain the original link to the transaction coverage by clicking on the "Deal Name."

图形用户界面, 应用程序

描述已自动生成

In the analysis view, you can see the most active assignors, assignees, popular targets, and other dimensions of analysis, as well as the distribution of research and development statuses at the time of the transaction, to help you better understand the search results.

图表

描述已自动生成

The Synapse database also supports the ability to view current transactions from the dimension of "drugs" (by selecting "drugs" from the "Adjust Dimension" dropdown menu above). Targeting transactions involving renowned pharmaceutical companies that are of interest to the industry, such as Merck, Roche, etc., Synapse has identified a group of "leading companies" through drugs that have achieved global sales exceeding 1 billion US dollars in 2022. Transactions involving drugs from these leading companies can be filtered by clicking on the "Leading Company" tag on the left-hand side.

图形用户界面, 应用程序, Teams

描述已自动生成

In addition to the drug transaction module, you can also view related transaction history on the drug detail page and the institution detail page.

图形用户界面, 文本, 应用程序

描述已自动生成

Click on the image below to embark on a brand new journey of drug discovery!

CARsgen shares fresh findings about CT041 at the ASCO GI Conference, 2024
Latest Hotspot
3 min read
CARsgen shares fresh findings about CT041 at the ASCO GI Conference, 2024
25 January 2024
At the 2024 ASCO GI Cancers Symposium, CARsgen Therapeutics presented study results for "satri-cel" (CT041), a Claudin18.2-targeted CAR-T therapy.
Read →
Exploring the Latest Potential "First-in-Class" Therapy Deal by Karuna Therapeutics: A Guide to Rapidly Accessing Transaction Insights
DrugDeal Decode
4 min read
Exploring the Latest Potential "First-in-Class" Therapy Deal by Karuna Therapeutics: A Guide to Rapidly Accessing Transaction Insights
25 January 2024
Bristol Myers Squibb (BMS) has agreed to acquire Karuna Therapeutics for around $14 billion, obtaining their novel schizophrenia treatment, KarXT.
Read →
Durvalumab (IMFINZI®) plus TACE and bevacizumab reduced liver cancer progression or mortality risk by 23%
Latest Hotspot
3 min read
Durvalumab (IMFINZI®) plus TACE and bevacizumab reduced liver cancer progression or mortality risk by 23%
25 January 2024
Durvalumab (IMFINZI®) combined with transarterial chemoembolization (TACE) and bevacizumab lowered the chance of liver cancer progression or death by 23%.
Read →
At the 2024 ASCO GI Symposium, Coherus presented promising Phase 2 results for the novel IL-27-targeted antibody, Casdozokitug
Latest Hotspot
3 min read
At the 2024 ASCO GI Symposium, Coherus presented promising Phase 2 results for the novel IL-27-targeted antibody, Casdozokitug
25 January 2024
At the 2024 ASCO GI Cancers Symposium, Coherus showcased encouraging Phase 2 trial results for Casdozokitug, an innovative IL-27-targeted antibody.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.